VERTEX PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
VERTEX PHARMACEUTICALS INC. - More news...
VERTEX PHARMACEUTICALS INC. - More news...
- Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
- Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
- Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
- Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
- Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
- Thinking about trading options or stock in Tesla, Energy Transfer, Paramount Global, Vertex Pharmaceuticals, or Broadcom ?
- Whittier Street Health Center to Honor Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden at Its 2024 Annual Gala
- Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
- Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics?
- Thinking about buying stock in Safe & Green Development, Esperion Therapeutics, Ford Motor, Vertex Pharmaceuticals, or LifeMD?
- Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
- Vertex Reports Second Quarter 2023 Financial Results
- European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
- Vertex to Announce Second Quarter 2023 Financial Results on August 1
- Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
- Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
- Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
- FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
- Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
- Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
- Vertex Reports First Quarter 2023 Financial Results
- Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
- Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
- Vertex to Announce First Quarter 2023 Financial Results on May 1
- Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
- Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
- Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
- Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
- Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
- Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
